Download PDF
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn¿s Disease and Ulcerative Colitis
Francisco Rodríguez-Moranta; Federico Argüelles-Arias; Joaquín Hinojosa del Val; Marisa Iborra Colomino; M. Dolores Martín-Arranz; Luis Menchén Viso; Fernando Muñoz Núñez; Elena Ricart Gómez; José Germán Sánchez-Hernández; Teresa Valdés-Delgado; Jordi Guardiola Capón; Manuel Barreiro-de Acosta; Míriam Mañosa Ciria; Yamile Zabana Abdo; Ana Gutiérrez Casbas;
Gastroenterol Hepatol. 2024;47:522-52
Body mass index does not influence loss of response to tumor necrosis factor inhibitors in Crohn's disease
Carla Bortolin Fonseca; Roberta Petry; Luciana Harlacher; Laryssa Hanauer; Carlos Fernando Magalhães Francesconi; Paulo Gustavo Kotze; Cristina Flores;
Gastroenterol Hepatol. 2025;48:
Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease
Javier Lucas Ramos; Cristina Suárez Ferrer; Joaquín Poza Cordón; María Sánchez Azofra; Jose Luis Rueda García; Eduardo Martin Arranz; Jorge Yebra Carmona; Irene Andaluz García; Maria Dolores Martín Arranz;
Gastroenterol Hepatol. 2021;44:337-45